Cencora, Inc. $COR Stock Holdings Lifted by Jones Financial Companies Lllp

Jones Financial Companies Lllp grew its stake in shares of Cencora, Inc. (NYSE:COR) by 34.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 6,833 shares of the company’s stock after acquiring an additional 1,735 shares during the period. Jones Financial Companies Lllp’s holdings in Cencora were worth $2,099,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of COR. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the period. Vermillion & White Wealth Management Group LLC lifted its stake in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after buying an additional 43 shares in the last quarter. Cloud Capital Management LLC purchased a new position in shares of Cencora in the third quarter worth approximately $31,000. Copia Wealth Management raised its holdings in shares of Cencora by 505.0% during the third quarter. Copia Wealth Management now owns 121 shares of the company’s stock valued at $38,000 after acquiring an additional 101 shares during the period. Finally, Caldwell Trust Co acquired a new stake in shares of Cencora during the second quarter valued at approximately $46,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 20,316 shares of company stock valued at $7,151,265. Corporate insiders own 0.38% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $359.15 on Monday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The firm has a market cap of $69.67 billion, a PE ratio of 43.17, a PEG ratio of 1.66 and a beta of 0.68. The firm’s 50 day moving average price is $345.91 and its 200 day moving average price is $326.38. Cencora, Inc. has a twelve month low of $237.71 and a twelve month high of $377.54.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping the consensus estimate of $4.04 by $0.04. The company had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.73 earnings per share. As a group, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is currently 28.85%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. TD Cowen lifted their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Evercore lowered their price target on Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a report on Thursday. Barclays initiated coverage on Cencora in a research report on Monday, December 8th. They set an “overweight” rating and a $400.00 price target on the stock. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Finally, Wells Fargo & Company upped their target price on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $394.75.

More Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Q1 2026 earnings call highlighted strong U.S. growth that offset international headwinds; management commentary helped support the upbeat tone after results. Cencora Inc (COR) Q1 2026 Earnings Call Highlights
• Positive Sentiment: Cencora closed its deal with OneOncology; coverage of the terms characterizes the agreement as reflecting trust between parties, which supports the company’s oncology services strategy and potential revenue synergies. As Cencora Closes With OneOncology
• Neutral Sentiment: Evercore ISI set a new $420 price target (down from $440) but kept an “outperform” rating — the target implies meaningful upside from current levels despite the trim. Cencora Given New $420.00 Price Target at Evercore ISI
• Neutral Sentiment: Market write-ups and stock-flow coverage are highlighting the mix of EPS beats and revenue dynamics as reasons for the intraday move, keeping attention on upcoming guidance and international performance. Cencora stock trades up, here is why
• Negative Sentiment: Cencora missed Q4 CY2025 revenue estimates, which tempers enthusiasm from the EPS beat and raises questions about near-term revenue momentum. Cencora misses Q4 revenue estimates
• Negative Sentiment: Recent intraday coverage noted the stock underperformed peers on Wednesday, suggesting investors are watching competitive execution and margin trends across the sector. Cencora underperforms competitors

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.